Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-19
2005-04-19
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06881739
ABSTRACT:
The present invention relates to the use of a cortisol antagonist in the manufacture of a medicament for the treatment of heart failure as well as to a method of treating heart failure which comprises administration of a cortisol antagonist and to a product containing (a) a cortisol antagonist and (b) a second drug as a combined preparation for simultaneous, separate or sequential use in the treatment of heart failure or in improving cardiac function and reducing exercise intolerance.
REFERENCES:
patent: 4603141 (1986-07-01), Giles
patent: 5175144 (1992-12-01), Walser
patent: 5565478 (1996-10-01), Kohn et al.
patent: 5654293 (1997-08-01), Francois
patent: 5756469 (1998-05-01), Beale
patent: 6362173 (2002-03-01), Schatzberg et al.
patent: 212051 (1996-01-01), None
patent: 221319 (2002-09-01), None
patent: WO 9200057 (1992-01-01), None
patent: 0018424 (2000-04-01), None
patent: 0024402 (2000-05-01), None
Faggiano P, D'Aloia A, Gualeni A, Giordano A. Hemodynamic profile of submaximal constant workload exercise i patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998 Fe 15;81(4):437-442.
Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional statu classification in patients with atrial fibrillation. New York Heart Association. Am Heart J May 1998; 135(5 Pt 1):819 824.
Spitz IM, Bardin CW. Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action. N Engl J Me Aug. 5, 1993; 329(6):404-412.
Scheuer DA, Mifflin SW. Chronic cortisone treatment increases myocardial infarct size in rats with ischemia reperfusion injury. Am J Physiol Jun. 1997; 272(6 Pt 2):R2017-2024.
Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: preparation and biologic activity. J Med Chem Jul. 24, 1992; 35(15):2818-2825.
Dvortsin GF. Use of a synthetic opioid for the reversal of stress-induced damage of the myocardium and gastr mucosa in severe thermal trauma [In Russian]. Kardiologiia Sep. 1989; 29(9):81-83.
Aggernaes H, Kirkegaard C, Magelund G. The effect of sodium valproate on serum cortisol levels in healthy subjec and depressed patients. Acta Psychiatr Scand Feb. 1988; 77(2):170-174.
Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Pucilowska J, Wierzbicki M, Jeske W. Effect of clonidine o beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity. Eur J Clin Pharmaco 1988;35(2):115-121.
Legros JJ, Chiodera P, Geenen V, von Frenckell R. Confirmation of the inhibitory influence of exogenous oxytocin o cortisol and ACTH in man: evidence of reproducibility. Acta Endocrinol (Copenh) Mar. 1987; 114(3):345-349.
Loose DS, Stover, EP, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucorticoi antagonist activity in cultured cells. J. Clin Invest Jul. 1983; 72(1):404-408.
Stubbs, WA, Delitala G, Jones A, Jeffcoate WJ, Edwards CR, Ratter SJ, Besser GM, Bloom SR, Alberti KG Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet Dec. 9, 1978; 2(8102):1225-1227.
Marin Per
Sorensen Sten
Baker & Botts LLP
Henley III Raymond J.
LandOfFree
Use of cortisol antagonists in the treatment of heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cortisol antagonists in the treatment of heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cortisol antagonists in the treatment of heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387253